Literature DB >> 16478651

Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites.

Vanessa Gonzalez Covarrubias1, Sukhwinder S Lakhman, Alan Forrest, Mary V Relling, Javier G Blanco.   

Abstract

In human liver, the two-electron reduction of quinone compounds, such as menadione is catalyzed by cytosolic carbonyl reductase (CBR) and NAD(P)H:quinone oxidoreductase (NQO1) activities. We assessed the relative contributions of CBR and NQO1 activities to the total menadione reducing capacity in liver cytosols from black (n=31) and white donors (n=63). Maximal menadione reductase activities did not differ between black (13.0+/-5.0 nmol/min mg), and white donors (11.4+/-6.6 nmol/min mg; p=0.208). In addition, both groups presented similar levels of CBR activities (CBR(blacks)=10.9+/-4.1 nmol/min mg) versus CBR(whites)=10.5+/-5.8 nmol/min mg; p=0.708). In contrast, blacks showed higher NQO1 activities (two-fold) than whites (NQO1(blacks)=2.1+/-3.0 nmol/min mg versus NQO1(whites)=0.9+/-1.6 nmol/min mg, p<0.01). To further explore this disparity, we tested whether NQO1 activity was associated with the common NQO1(*)2 genetic polymorphism by using paired DNA samples for genotyping. Cytosolic NQO1 activities differed significantly by NQO1 genotype status in whites (NQO1(whites[NQO1*1/*1])=1.3+/-1.7 nmol/min mg versus NQO1(whites[NQO1*1/*2+NQO1*2/*2])=0.5+/-0.7 nmol/min mg, p<0.01), but not in blacks (NQO1(blacks[NQO1*1/*1])=2.6+/-3.4 nmol/min mg versus NQO1(blacks[NQO1*1/*2])=1.1+/-1.2 nmol/min mg, p=0.134). Our findings pinpoint the presence of significant interethnic differences in polymorphic hepatic NQO1 activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16478651      PMCID: PMC3359862          DOI: 10.1016/j.toxlet.2006.01.004

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  37 in total

1.  The importance of race and ethnic background in biomedical research and clinical practice.

Authors:  Esteban González Burchard; Elad Ziv; Natasha Coyle; Scarlett Lin Gomez; Hua Tang; Andrew J Karter; Joanna L Mountain; Eliseo J Pérez-Stable; Dean Sheppard; Neil Risch
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

Review 2.  Pharmacogenetics and geographical ancestry: implications for drug development and global health.

Authors:  Abdallah S Daar; Peter A Singer
Journal:  Nat Rev Genet       Date:  2005-03       Impact factor: 53.242

Review 3.  NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

Authors:  D Ross; J K Kepa; S L Winski; H D Beall; A Anwar; D Siegel
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

Review 4.  Carbonyl reductase.

Authors:  G L Forrest; B Gonzalez
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

5.  Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.

Authors:  Javier G Blanco; Mathew J Edick; Michael L Hancock; Naomi J Winick; Thierry Dervieux; Michael D Amylon; Robert O Bash; Frederick G Behm; Bruce M Camitta; Ching-Hon Pui; Susana C Raimondi; Mary V Relling
Journal:  Pharmacogenetics       Date:  2002-11

6.  Brachial vascular reactivity in blacks.

Authors:  D Perregaux; A Chaudhuri; S Rao; A Airen; M Wilson; B H Sung; P Dandona
Journal:  Hypertension       Date:  2000-11       Impact factor: 10.190

7.  Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

Authors:  Ronald A Fleming; Jeffrey Drees; Brian W Loggie; Gregory B Russell; Kim R Geisinger; Reba T Morris; Debbie Sachs; Richard P McQuellon
Journal:  Pharmacogenetics       Date:  2002-01

8.  Race-specific differences in antioxidant enzyme activity in patients with type 2 diabetes: a potential association with the risk of developing nephropathy.

Authors:  Karima Zitouni; Jaffar Nourooz-Zadeh; Diane Harry; Sally M Kerry; D John Betteridge; Francesco P Cappuccio; Kenneth A Earle
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

9.  Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues.

Authors:  D Siegel; D Ross
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

10.  Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

Authors:  D Siegel; A Anwar; S L Winski; J K Kepa; K L Zolman; D Ross
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

View more
  7 in total

1.  Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.

Authors:  Jianping Zhang; Javier G Blanco
Journal:  Pharm Res       Date:  2009-07-10       Impact factor: 4.200

2.  Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.

Authors:  Adam Bress; Shitalben R Patel; Minoli A Perera; Richard T Campbell; Rick A Kittles; Larisa H Cavallari
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

3.  Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Authors:  Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

4.  Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.

Authors:  Vanessa Gonzalez-Covarrubias; Jianping Zhang; James L Kalabus; Mary V Relling; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2008-11-20       Impact factor: 3.922

5.  A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.

Authors:  Vanessa Gonzalez-Covarrubias; Debashis Ghosh; Sukhwinder S Lakhman; Lakshmi Pendyala; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2007-03-07       Impact factor: 3.922

6.  Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity.

Authors:  Ruth A Morgan; Katharina R Beck; Mark Nixon; Natalie Z M Homer; Andrew A Crawford; Diana Melchers; René Houtman; Onno C Meijer; Andreas Stomby; Anna J Anderson; Rita Upreti; Roland H Stimson; Tommy Olsson; Tom Michoel; Ariella Cohain; Arno Ruusalepp; Eric E Schadt; Johan L M Björkegren; Ruth Andrew; Christopher J Kenyon; Patrick W F Hadoke; Alex Odermatt; John A Keen; Brian R Walker
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

7.  Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.

Authors:  Shalenie P den Braver-Sewradj; Michiel W den Braver; Robin M Toorneman; Stephanie van Leeuwen; Yongjie Zhang; Stefan J Dekker; Nico P E Vermeulen; Jan N M Commandeur; J Chris Vos
Journal:  Chem Res Toxicol       Date:  2018-01-11       Impact factor: 3.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.